Charles Schwab’s Akero Therapeutics AKRO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $32.8M | Buy |
614,266
+32,012
| +5% | +$1.71M | 0.01% | 1370 |
|
|
2025
Q1 | $23.6M | Buy |
582,254
+41,562
| +8% | +$1.68M | ﹤0.01% | 1549 |
|
|
2024
Q4 | $15M | Buy |
540,692
+8,096
| +2% | +$225K | ﹤0.01% | 1837 |
|
|
2024
Q3 | $15.3M | Sell |
532,596
-22,269
| -4% | -$639K | ﹤0.01% | 1837 |
|
|
2024
Q2 | $13M | Buy |
554,865
+36,579
| +7% | +$858K | ﹤0.01% | 1907 |
|
|
2024
Q1 | $13.1M | Buy |
518,286
+92,741
| +22% | +$2.34M | ﹤0.01% | 1843 |
|
|
2023
Q4 | $9.94M | Buy |
425,545
+6,115
| +1% | +$143K | ﹤0.01% | 1990 |
|
|
2023
Q3 | $21.2M | Buy |
419,430
+124,768
| +42% | +$6.31M | 0.01% | 1474 |
|
|
2023
Q2 | $13.8M | Buy |
294,662
+56,315
| +24% | +$2.63M | ﹤0.01% | 1740 |
|
|
2023
Q1 | $9.12M | Buy |
238,347
+1,750
| +0.7% | +$67K | ﹤0.01% | 1917 |
|
|
2022
Q4 | $13M | Buy |
236,597
+23,578
| +11% | +$1.29M | ﹤0.01% | 1704 |
|
|
2022
Q3 | $7.25M | Buy |
213,019
+48,196
| +29% | +$1.64M | ﹤0.01% | 2018 |
|
|
2022
Q2 | $1.56M | Sell |
164,823
-8,723
| -5% | -$82.5K | ﹤0.01% | 2639 |
|
|
2022
Q1 | $2.46M | Sell |
173,546
-706
| -0.4% | -$10K | ﹤0.01% | 2570 |
|
|
2021
Q4 | $3.69M | Buy |
174,252
+8,899
| +5% | +$188K | ﹤0.01% | 2502 |
|
|
2021
Q3 | $3.7M | Buy |
165,353
+26,360
| +19% | +$589K | ﹤0.01% | 2512 |
|
|
2021
Q2 | $3.45M | Buy |
138,993
+27,882
| +25% | +$692K | ﹤0.01% | 2529 |
|
|
2021
Q1 | $3.22M | Buy |
111,111
+3,179
| +3% | +$92.2K | ﹤0.01% | 2504 |
|
|
2020
Q4 | $2.79M | Buy |
107,932
+119
| +0.1% | +$3.07K | ﹤0.01% | 2491 |
|
|
2020
Q3 | $3.32M | Buy |
107,813
+56,868
| +112% | +$1.75M | ﹤0.01% | 2280 |
|
|
2020
Q2 | $1.27M | Buy |
50,945
+6,619
| +15% | +$165K | ﹤0.01% | 2558 |
|
|
2020
Q1 | $940K | Buy |
44,326
+8,102
| +22% | +$172K | ﹤0.01% | 2505 |
|
|
2019
Q4 | $804K | Buy |
36,224
+3,935
| +12% | +$87.3K | ﹤0.01% | 2670 |
|
|
2019
Q3 | $735K | Buy |
+32,289
| New | +$735K | ﹤0.01% | 2658 |
|